Clinical trial
Study of BMS-663513 in Patients With Advanced Cancer
NCT00309023 · Bristol-Myers Squibb, Industry · Terminated
Key facts
| NCT number | NCT00309023 |
|---|---|
| Title | Study of BMS-663513 in Patients With Advanced Cancer |
| Official title | A Phase I/II, Ascending Multi-Dose Study of BMS-663513, An Agonistic Anti-CD137 Monoclonal Antibody, Administered Every Three Weeks to Patients With Metastatic or Locally Advanced Solid Malignancies |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Status | Terminated |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Tumors |
| Intervention type | Drug |
| Interventions | BMS-663513 |
| Enrollment | 115 |
| Start date | Dec 1, 2005 |
| Primary completion | Dec 1, 2008 |
| Completion | Sep 1, 2009 |
| First posted | Mar 31, 2006 |
| Last update posted | Oct 12, 2015 |
| Countries | Canada, France, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: